Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial - Concepedia

Concepedia

Publication | Closed Access

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial

92

Citations

9

References

2011

Year

Robert Bissonnette, Yves Poulin, Yabo Zhou, Jin Tan, H. Chih ho Hong, J. Webster, Wan Ip, Lisa Tang, M. Lyle

British Journal of Dermatology

Abstract

WBI-1001 is an efficacious novel topical anti-inflammatory molecule for the treatment of AD.

References

	Year	Citations

Page 1